We observed that genes associated with doxorubicin (topoisomerase II inhibitor) and cisplatin (DNA cross linking agent; promising therapy for BRCA1/2 mutated/deficient tumors) resistance in gastric cancer cell lines and patients, respectively were significantly enriched in patients with low miR-644a signature scores (Supplementary Table S3). Here, BRCA1 is linked to gastric cancer.